April 2012
- LRG mourns the loss of a great friend, Jeroen Pit
- GDOL Update: Speakers announced
- LRG Research Team meets in Leuven, Belgium: leaves with renewed energy & commitment to finding the cure for GIST
- Meet our new Montana local rep: Dirk Niebaum
- Cellular origin of GIST from the “good” cells’ perspective
- Alianza GIST meets in Miami
- And they’re off! 1st ‘Harness a Cure’ is a success
- NJ GIST gathering serves up support & smoothies
- NoCal GISTers meet!
- New report finds most hospital errors go unreported
- Happy Cancerversary to Brenda Bannon!
- Thomas G. Overley, 1952-2012: Toledo lawyer played guitar, sang in group
- Durham lived life with passion and pride
- Did You Hear? Did You Know?
- Arizona GISTers meet!
- Spunky Texan fought GIST bravely
- Calendar
Archive
June 2009
June 2009 clinical trials update
Written by
Jim Hughes
BKM120 Phase 1: A new Novartis PI3K inhibitor, BMK120, is now recruiting at Sarah Cannon in Nashville, Tenn. As with most Phase 1 trials, this trial is for “Solid Tumors” which should include GIST. BMK120 inhibits PI3K but unlike the other Novartis PI3K inhibitors, BEZ235 and BGT226, it does not also inhibit mTOR.
Nilotinib Versus Imatinib: 15 new sites are listed as recruiting in Austria, Brazil, Canada and Japan
View the Clinical Trials Bulletin
0 Comments